Discovery of 2-(1H-imidazo-2-yl)piperazines as a new class of potent and non-cytotoxic inhibitors of Trypanosoma brucei growth in vitro.

[1]  David Horn,et al.  Melarsoprol Resistance in African Trypanosomiasis. , 2018, Trends in parasitology.

[2]  D. Tshala-Katumbay,et al.  Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo , 2018, PLoS neglected tropical diseases.

[3]  Giuliano Cecchi,et al.  Human African trypanosomiasis , 2017, The Lancet.

[4]  Ian H. Gilbert,et al.  Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need , 2017, Nature Reviews Microbiology.

[5]  Jessica A. Engel,et al.  Design and Synthesis of Novel Anti‐Plasmodial Histone Deacetylase Inhibitors Containing an Alkoxyamide Connecting Unit , 2017, Archiv der Pharmazie.

[6]  A. Mai,et al.  Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives. , 2017, Journal of medicinal chemistry.

[7]  V. Lather,et al.  Recent Updates on Development of Drug Molecules for Human African Trypanosomiasis. , 2016, Current topics in medicinal chemistry.

[8]  S. Harper,et al.  Discovery of a Selective Series of Inhibitors of Plasmodium falciparum HDACs. , 2016, ACS medicinal chemistry letters.

[9]  F. Chappuis,et al.  Treatment options for second-stage gambiense human African trypanosomiasis , 2014, Expert review of anti-infective therapy.

[10]  Ana Rodriguez,et al.  Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery. , 2014, MedChemComm.

[11]  A. Holmgren,et al.  Ebsulfur Is a Benzisothiazolone Cytocidal Inhibitor Targeting the Trypanothione Reductase of Trypanosoma brucei * , 2013, The Journal of Biological Chemistry.

[12]  I. Gilbert,et al.  From On-Target to Off-Target Activity: Identification and Optimisation of Trypanosoma brucei GSK3 Inhibitors and Their Characterisation as Anti-Trypanosoma brucei Drug Discovery Lead Molecules , 2013, ChemMedChem.

[13]  Michel Quere,et al.  Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  E. Fèvre,et al.  Estimating and Mapping the Population at Risk of Sleeping Sickness , 2012, PLoS neglected tropical diseases.

[15]  C. Burri,et al.  Safety and Efficacy of the 10-Day Melarsoprol Schedule for the Treatment of Second Stage Rhodesiense Sleeping Sickness , 2012, PLoS neglected tropical diseases.

[16]  Michael J. Zdilla,et al.  Enantioselective synthesis of cocaine C-1 analogues using sulfinimines (N-sulfinyl imines). , 2012, The Journal of organic chemistry.

[17]  L. Scapozza,et al.  Crystal Structures of T. b. rhodesiense Adenosine Kinase Complexed with Inhibitor and Activator: Implications for Catalysis and Hyperactivation , 2011, PLoS neglected tropical diseases.

[18]  M. Phillips,et al.  State of the art in African trypanosome drug discovery. , 2011, Current topics in medicinal chemistry.

[19]  F. A. Davis,et al.  Asymmetric synthesis of substituted homotropinones from N-sulfinyl beta-amino ketone ketals. (-)-Euphococcinine and (-)-adaline. , 2010, Organic letters.

[20]  Stuart P. McElroy,et al.  Investigation of Trypanothione Reductase as a Drug Target in Trypanosoma brucei , 2009, ChemMedChem.

[21]  M. Rowley,et al.  Metabolism-related liabilities of a potent histone deacetylase (HDAC) inhibitor and relevance of the route of administration on its metabolic fate , 2009, Xenobiotica; the fate of foreign compounds in biological systems.

[22]  L. Scapozza,et al.  Adenosine Kinase of T. b. rhodesiense Identified as the Putative Target of 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine Using Chemical Proteomics , 2009, PLoS neglected tropical diseases.

[23]  Salah Ghabri,et al.  Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial , 2009, The Lancet.

[24]  M. Rowley,et al.  Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties. , 2009, Journal of medicinal chemistry.

[25]  Timothy N C Wells,et al.  Glycogen Synthase Kinase 3 Is a Potential Drug Target for African Trypanosomiasis Therapy , 2008, Antimicrobial Agents and Chemotherapy.

[26]  R. De Francesco,et al.  A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo. , 2008, Journal of medicinal chemistry.

[27]  G. Cross,et al.  Acetylation of histone H4K4 is cell cycle regulated and mediated by HAT3 in Trypanosoma brucei , 2007, Molecular microbiology.

[28]  G. Priotto,et al.  Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  B. Mpia,et al.  Randomized controlled trial of three regimens of melarsoprol in the treatment of Trypanosoma brucei gambiense trypanosomiasis. , 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[30]  Ching C. Wang,et al.  An Aurora Kinase Homologue Is Involved in Regulating Both Mitosis and Cytokinesis in Trypanosoma brucei* , 2006, Journal of Biological Chemistry.